Patents by Inventor DANIEL HASSAN

DANIEL HASSAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10888522
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Publication number: 20200383949
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Application
    Filed: August 25, 2020
    Publication date: December 10, 2020
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20200268887
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20200268886
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10751323
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: August 25, 2020
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20200230059
    Abstract: A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 ?m to 40 ?m, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 23, 2020
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20200163886
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Application
    Filed: December 3, 2018
    Publication date: May 28, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Patent number: 10586037
    Abstract: A technique communicates a password to a user. The technique involves receiving, by processing circuitry, a request for a password. The technique further involves generating, by the processing circuitry, a password in response to the request. The password includes a series of alphanumeric digits which contains at least one number and at least one letter. The technique further involves displaying, by the processing circuitry, the password on a display screen. Each number displayed on the display screen has a first visual characteristic, and each letter displayed on the display screen has a visual characteristic that is different from the first visual characteristic. Such a technique enables disambiguation of an alphanumeric security code to a user.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 10, 2020
    Assignee: EMC IP Holding Company LLC
    Inventors: Bharath Krishnappa, Netravati V. Hegadi, Daniel Hassan
  • Publication number: 20200069803
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10500280
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 10, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Publication number: 20190328881
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 31, 2019
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20190321475
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 24, 2019
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Publication number: 20190269653
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.
    Type: Application
    Filed: March 11, 2019
    Publication date: September 5, 2019
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 10342873
    Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: July 9, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
  • Patent number: 10226447
    Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin. The dosage form is effective to release melatonin therefrom for at least six hours after oral ingestion.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 12, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan
  • Publication number: 20190031417
    Abstract: Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 ?m to 270 ?m coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/m2 to 130 g/m2. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 ?m to 30 ?m.
    Type: Application
    Filed: July 26, 2018
    Publication date: January 31, 2019
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan
  • Publication number: 20180360967
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10143654
    Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
  • Patent number: D907760
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 12, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Daniel Hassan, Fred Hassan